Unusual adverse reactions to GLP-1 receptor agonists: A structured review of the literature
PDF (Español (España))

Keywords

Glucagon-Like Peptide-1 Receptor Agonists
Obesity
Diabetes Mellitus
Drug-Related Side Effects and Adverse Reactions
Mental Disorders
Biliary Tract Diseases
Macular Diseases
Thyroid Neoplasms

How to Cite

Jimenez Canizales, C. E., Gálvez Garrido, L. S. ., & Rojas-Gómez, O. F. . (2026). Unusual adverse reactions to GLP-1 receptor agonists: A structured review of the literature. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 13(4). https://doi.org/10.53853/encr.13.4.1068

Abstract

Background: The use of GLP-1 receptor agonists (GLP-1 agonists) as a treatment for obesity and diabetes is growing rapidly. Their use has taken place without a comprehensive understanding of the full spectrum of their potential rare adverse reactions.

Objective: The aim of this study was to conduct a structured literature search and describe the rare adverse reactions associated with GLP-1 agonists.

Methods: A literature search was conducted between January and November 2026, with supplementary searches performed throughout manuscript preparation to incorporate recent evidence. No restrictions were imposed on publication year, given the importance of including both foundational studies essential for understanding the underlying pathophysiological mechanisms and recent research findings. Publications were selected based on their relevance to the research question: ‘What are the rare adverse reactions associated with the use of arGLP-1 and what is their clinical relevance?’ using the MeSH descriptors: ‘Glucagon-Like Peptide 1 Receptor Agonists’ and “Drug-Related Side Effects and Adverse Reactions”, combined with terms related to frequency (“Rare”, “Uncommon”) and clinical relevance (“Treatment Outcome”, “Risk Assessment”), as well as free-text terms related to specific drugs (semaglutide, liraglutide, and tirzepatide) and their potential adverse effects, including "hair loss," "alopecia," "telogen effluvium," "facial volume loss," and "Ozempic face," in the PubMed® and Scopus databases.

Results: Most of the adverse reactions evaluated by the systems were rare; nevertheless, the importance of close monitoring with these molecules should not be overlooked, as they are not without complications, and the GLP-1 receptor is expressed in multiple organs.

Conclusion: Healthcare professionals must make individualised decisions based on a full understanding of the spectrum of potential effects of these drugs, which are currently in vogue.

https://doi.org/10.53853/encr.13.4.1068
PDF (Español (España))

References

Cruz-Rojas JD, Jiménez-Canizales CE, Bahamón-Rivera H. Perspectivas en el manejo de la obesidad según la evidencia actual. Acta Méd Col. 2025; 50(3 Supl). https://doi.org/10.36104/amc.2025.4884

Christensen RM, Juhl CR, Torekov SS. Benefit-risk assessment of obesity drugs: Focus on glucagon-like peptide-1 receptor agonists. Drug Saf. 2019; 42: 957-71. https://doi.org/10.1007/s40264-019-00812-7

He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022; 182(5): 513-519. https://doi.org/10.1001/jamainternmed.2022.0338

Ionut Feier CV, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (ozempic) therapy for diabetes mellitus and obesity: A systematic literature review. Int J Mol Sci. 2024; 25(8), 4346. https://doi.org/10.3390/ijms25084346

Liu Y, He L, Han S, Ping F, Li W, Xu L, et al. Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2025; 14(9): e039446. https://doi.org/10.1161/JAHA.124.039446

Tang H, Lu Y, Donahoo WT, Westen SC, Chen Y, Bian J, et al. Glucagon-like peptide-1 receptor agonists and risk for depression in older adults with type 2 diabetes: A target trial emulation study. Ann Intern Med. 2025; 178(3): 315-326. https://doi.org/10.7326/ANNALS-24-01347

Taipale H, Taylor M, Lähteenvuo M, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: A national cohort study. Lancet Psychiatry. 2026; 13(4): 327-335. https://doi.org/10.1016/S2215-0366(26)00014-3

Lakhani M, Kwan ATH, Mihalache A, Popovic MM, Nanji K, Xie JS, et al. Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: A population-based observational study across 180 countries. Am J Ophthalmol. 2025; 277: 148-168. https://doi.org/10.1016/j.ajo.2025.05.007

Liu L, Mohan S, Wu L. GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy: What an endocrinologist needs to know. J Clin Endocrinol Metab. 2026; 111(1): e308-e313. https://doi.org/10.1210/clinem/dgaf541

Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, et al. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: A meta-analysis of randomized controlled trials. Front Endocrinol. 2022; 13: 927859. https://doi.org/10.3389/fendo.2022.927859

Morales DR, Bu F, Viernes B, DuVall SL, Matheny ME, Simon KR, et al. Risk of thyroid tumors with GLP-1 receptor agonists: A retrospective cohort study. Diabetes Care. 2025; 48(8): 1386-1394. https://doi.org/10.2337/dc25-0154

Gallagher TJ, Razura DE, Li A, Kim I, Vukkadala N, Barbu AM. Glucagon-like peptide-1 receptor agonists and chronic cough. JAMA Otolaryngol Head Neck Surg. 2026; 152(2): 163-171. https://doi.org/10.1001/jamaoto.2025.4181

Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials. Int J Surg. 2024; 110(8): 4688-4694. https://doi.org/10.1097/JS9.0000000000001514

Lu Y, Dai H, Tang H, Donahoo WT, George TJ, Sun RC, et al. Association of glucagon-like peptide-1 receptor agonists with cancer risk in older adults with type 2 diabetes. Obesity. 2025; 34(52): 75-87. https://doi.org/10.1002/oby.24366

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373: 11-22. https://doi.org/10.1056/NEJMoa1411892

Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The Scale diabetes randomized clinical trial. JAMA. 2015; 314(7): 687-699. https://doi.org/10.1001/jama.2015.9676

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834-1844. https://doi.org/10.1056/NEJMoa1607141

Alfakhri A, Almadani O, Alroba R, Alrwisan A, Alshaya O, Albogami Y. The risk of hypothyroidism with the use of GLP-1 receptor agonists in Saudi Arabia. Pharmacoepidemiol Drug Saf. 2026; 35(1): e70315. https://doi.org/10.1002/pds.70315

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (Rewind): A double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193): 121-30. https://doi.org/10.1016/S0140-6736(19)31149-3

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375: 311-322. https://doi.org/10.1056/NEJMoa1603827

Pasternak B, Wintzell V, Hviid A, Eliasson B, Gudbjörnsdottir S, Jonasson C, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024; 385: e078225. https://doi.org/10.1136/bmj-2023-078225

Yin DG, Ding LL, Zhou HR, Qiu M, Duan XY. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: A meta-analysis of the Sustain and Pioneer trials. Endocr J. 2021; 68(6): 739-742. https://doi.org/10.1507/endocrj.EJ21-0129

Rosen CJ, Ingelfinger JR. GLP-1 receptor agonists. N Engl J Med. 2026; 394(13): 1313-1324. https://doi.org/10.1056/NEJMra2500106

Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (Step 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10278): 971-984. https://doi.org/10.1016/S0140-6736(21)00213-0

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228-1239. https://doi.org/10.1056/NEJMoa1612917

Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2?years in metformin-treated patients with type 2 diabetes (Award-5): A randomized, phase III study. Diabetes Obes Metab. 2015; 17(9): 849-858. https://doi.org/10.1111/dom.12479

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373(23): 2247-2257. https://doi.org/10.1056/NEJMoa1509225

Fathizadeh BS, Hwang MAS, Hoss ME. Ozempic face and facial aging. Clinics in Dermatology. Elsevier; 2026. https://doi.org/10.1016/j.clindermatol.2026.10.004

Seyed Jafari SM, Caro G, Lipner SR, Iorizzo M. The impact of GLP-1 receptor agonists on hair: Beneficial effects or adverse outcomes? Am J Clin Dermatol. 2026; 27: 579-586. https://doi.org/10.1007/s40257-026-01021-6

Jensen SBK, Sørensen V, Sandsdal RM, Lehmann EW, Lundgren JR, Juhl CR, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: A secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024; 7(6): e2416775. https://doi.org/10.1001/jamanetworkopen.2024.16775

Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025; 393(18): 1796-1806. https://doi.org/10.1056/NEJMoa2511774

Rubin R. Data on 3 new GLP-1 Drugs for weight loss that may be approved this year. JAMA. 2026; 335(8): 653-655. https://doi.org/10.1001/jama.2026.0287

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205-216. https://doi.org/10.1056/NEJMoa2206038

Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024; 391(13): 1193-1205. https://doi.org/10.1056/NEJMoa2404881

Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021; 384:1113-1124. https://doi.org/10.1056/NEJMoa2028395

Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025; 392: 2089-2099. https://doi.org/10.1056/NEJMoa2413258

U.S. Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. 2026 https://www.fda.gov/media/190557/download

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2026 Revista Colombiana de Endocrinología, Diabetes & Metabolismo

Dimensions


PlumX


Downloads

Download data is not yet available.